del Río Cantero, NataliaMourelle Martínez, RosaSagastizábal Cardelús, BelénNova García, Manuel Joaquín De2024-03-202024-03-202024-03-06Del Rio Cantero N, Mourelle Martínez MR, Sagastizabal Cardelús B, De Nova García JM. Influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta. Bone. 2024 Mar 6;182:1170698756-328210.1016/j.bone.2024.117069https://hdl.handle.net/20.500.14352/102438Introduction: Osteogenesis imperfecta (OI) is a congenital disease comprising a heterogeneous group of inherited connective tissue disorders. The main treatment in children is bisphosphonate therapy. Previous animal studies have shown that bisphosphonates delay tooth eruption. The aim of this study is to determine whether patients with OI treated with pamidronate and/or zoledronic acid have a delayed eruption age compared to a control group of healthy children. Methods: An ambispective longitudinal cohort study evaluating the age of eruption of the first stage mixed dentition in a group of children with OI (n = 37) all treated with intravenous bisphosphonates compared with a group of healthy children (n = 89). Within the study group, the correlation (Pearson correlation test) between the type of medication administered (pamidronate and/or zoledronic acid) and the chronology of tooth eruption is established, as well as the relationship between the amount of cumulative dose received and tooth eruption. Results: The age of eruption of the study group was significantly delayed compared to the age of eruption of the control group for molars and lateral incisors (p < 0.05). Patients who received higher cumulative doses had a delayed eruption age compared to those with lower cumulative doses (p < 0.05). There is a high positive correlation between age of delayed tooth eruption and Zoledronic acid administration. Conclusion: Patients with OI have a delayed eruption of the 1st stage mixed dentition compared to a control group of healthy children. This delayed eruption is directly related to the cumulative dose of bisphosphonates and the administration of zoledronic ac.engAttribution 4.0 Internationaljournal article1873-2763https://www.sciencedirect.com/science/article/pii/S8756328224000589?via%3Dihub38458305open access616-053.2616.314-053.2616.71BisphosphonatesDental eruptionOsteogenesis imperfectaPamidronateZoledronic acidCiencias BiomédicasOdontología (Medicina)Odontología infantilMedicamentos32 Ciencias Médicas3207.14 Osteopatología